| Symbol | AGMB |
|---|---|
| Name | AGOMAB THERAPEUTICS NV |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | POSTHOFLEI 1/6, ANTWERPEN, 2600, Belgium |
| Telephone | +32 3318 9170 |
| Fax | — |
| — | |
| Website | www.agomab.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0002020932 |
| Description | AgomAb Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Our product candidates are designed to target established pathways and utilize validated modalities with the aim of increasing efficacy while avoiding systemic toxicities in order to overcome the limitations of prior therapeutic approaches. Additional info from NASDAQ: |
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
Read moreAgomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
Read moreAgomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
Read moreNew Form SCHEDULE 13G - Agomab Therapeutics NV <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001104659-26-062718 <b>Size:</b> 12 KB
Read moreNew Form SCHEDULE 13G - Agomab Therapeutics NV <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001172661-26-002216 <b>Size:</b> 10 KB
Read moreNew Form SCHEDULE 13G - Agomab Therapeutics NV <b>Filed:</b> 2026-05-06 <b>AccNo:</b> 0001193125-26-207455 <b>Size:</b> 7 KB
Read moreAgomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
Read more